Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 1434872, 10 pages
https://doi.org/10.1155/2017/1434872
Research Article

Chemokines (CCL3, CCL4, and CCL5) Inhibit ATP-Induced Release of IL-1β by Monocytic Cells

1Laboratory of Experimental Surgery, Department of General and Thoracic Surgery, Justus-Liebig-University Giessen, Giessen, Germany
2Department of Biochemistry, Faculty of Medicine, Universities of Giessen and Marburg Lung Center, Giessen, Germany
3George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, UT, USA
4Department of Biology, University of Utah, Salt Lake City, UT, USA
5Department of Psychiatry, University of Utah, Salt Lake City, UT, USA
6Excellence Cluster Cardiopulmonary System (ECCPS), German Center for Lung Research (DZL), Giessen, Germany

Correspondence should be addressed to Veronika Grau; ed.nesseig-inu.dem.urihc@uarg.akinorev

Received 20 January 2017; Revised 31 March 2017; Accepted 20 April 2017; Published 5 July 2017

Academic Editor: Paul Proost

Copyright © 2017 Anca-Laura Amati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. M. Stoecklein, A. Osuka, and J. A. Lederer, “Trauma equals danger—damage control by the immune system,” Journal of Leukocyte Biology, vol. 92, no. 3, pp. 539–551, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Surbatovic, M. Veljovic, J. Jevdjic, N. Popovic, D. Djordjevic, and S. Radakovic, “Immunoinflammatory response in critically ill patients: severe sepsis and/or trauma,” Mediators of Inflammation, vol. 2013, Article ID 362793, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Lord, M. J. Midwinter, Y. F. Chen et al., “The systemic immune response to trauma: an overview of pathophysiology and treatment,” Lancet, vol. 384, no. 9952, pp. 1455–1465, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Cekic and J. Linden, “Purinergic regulation of the immune system,” Nature Reviews Immunology, vol. 16, no. 3, pp. 177–192, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. R. A. Namas, Q. Mi, R. Namas et al., “Insights into the role of chemokines, damage-associated molecular patterns, and lymphocyte-derived mediators from computational models of trauma-induced inflammation,” Antioxidants & Redox Signaling, vol. 23, no. 17, pp. 1370–1387, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. E. S. Alnemri, “Sensing cytoplasmic danger signals by the inflammasome,” Journal of Clinical Immunology, vol. 30, no. 4, pp. 512–519, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. O. Gross, C. J. Thomas, G. Guarda, and J. Tschopp, “The inflammasome: an integrated view,” Immunological Reviews, vol. 243, no. 1, pp. 136–151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Lamkanfi and V. M. Dixit, “Mechanisms and functions of inflammasomes,” Cell, vol. 157, no. 5, pp. 1013–1022, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. G. I. Vladimer, R. Marty-Roix, S. Ghosh, D. Weng, and E. Lien, “Inflammasomes and host defenses against bacterial infections,” Current Opinion in Microbiology, vol. 16, no. 1, pp. 23–31, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. C. A. Dinarello, A. Simon, and J. W. van der Meer, “Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases,” Nature Reviews Drug Discovery, vol. 11, no. 8, pp. 633–652, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Bergsbaken, S. L. Fink, and B. T. Cookson, “Pyroptosis: host cell death and inflammation,” Nature Reviews Microbiology, vol. 7, no. 2, pp. 99–109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Viola and A. D. Luster, “Chemokines and their receptors: drug targets in immunity and inflammation,” Annual Review of Pharmacology and Toxicology, vol. 48, pp. 171–197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Thelen, “Dancing to the tune of chemokines,” Nature Immunology, vol. 2, no. 2, pp. 129–134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Muller, “New mechanisms and pathways for monocyte recruitment,” Journal of Experimental Medicine, vol. 194, no. 9, pp. F47–F51, 2001. View at Publisher · View at Google Scholar
  15. C. Shi and E. G. Pamer, “Monocyte recruitment during infection and inflammation,” Nature Reviews Immunology, vol. 11, no. 11, pp. 762–774, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Whiteaker, S. Christensen, D. Yoshikami et al., “Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist,” Biochemistry, vol. 46, no. 22, pp. 6628–6638, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Innocent, P. D. Livingstone, A. Hone et al., “Alpha-conotoxin Arenatus IB [V11L,V16D] is a potent and selective antagonist at rat and human native alpha7 nicotinic acetylcholine receptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 327, no. 2, pp. 529–537, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Richter, V. Mathes, M. Fronius et al., “Phosphocholine—an agonist of metabotropic but not of ionotropic functions of α9-containing nicotinic acetylcholine receptors,” Scientific Reports, vol. 6, article 28660, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. H. K. Romero, S. B. Christensen, L. DiCesare Mannelli et al., “Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 114, pp. E1825–E1832, 2017. View at Publisher · View at Google Scholar
  20. A. Hecker, M. Küllmar, S. Wilker et al., “Phosphocholine-modified macromolecules and canonical nicotinic agonists inhibit ATP-induced IL-1β release,” Journal of Immunology, vol. 195, no. 5, pp. 2325–2334, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Kawashima, T. Fujii, Y. Moriwaki, and H. Misawa, “Critical roles of acetylcholine and the muscarinic and nicotinic acetylcholine receptors in the regulation of immune function,” Life Sciences, vol. 91, no. 21-22, pp. 1027–1032, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. J. E. Burke and E. A. Dennis, “Phospholipase A2 structure/function, mechanism, and signaling,” Journal of Lipid Research, vol. 50 Supplement, pp. S237–S242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Ramanadham, T. Ali, J. W. Ashley, R. N. Bone, W. D. Hancock, and X. Lei, “Calcium-independent phospholipases A2 and their roles in biological processes and diseases,” Journal of Lipid Research, vol. 56, no. 9, pp. 1643–1668, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. K. A. Carnevale and M. K. Cathcart, “Calcium-independent phospholipase A(2) is required for human monocyte chemotaxis to monocyte chemoattractant protein 1,” Journal of Immunology, vol. 167, no. 6, pp. 3414–3421, 2001. View at Publisher · View at Google Scholar
  25. R. S. Mishra, K. A. Carnevale, and M. K. Cathcart, “iPLA2beta: front and center in human monocyte chemotaxis to MCP-1,” Journal of Experimental Medicine, vol. 205, no. 2, pp. 347–359, 2008. View at Publisher · View at Google Scholar · View at Scopus